The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments.
‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and...
SAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and...
The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.68 per share in cash. The record date for this distribution is November 29, 2024...
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management...
Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare...
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0014 | -0.0144628099174 | 9.68 | 9.84 | 9.17 | 4204 | 9.63638152 | CS |
4 | -1.0914 | -10.1337047354 | 10.77 | 10.77 | 9.17 | 4245 | 9.77658003 | CS |
12 | -0.1514 | -1.54018311292 | 9.83 | 10.99 | 8.85 | 6972 | 9.95177519 | CS |
26 | 0.1486 | 1.5592864638 | 9.53 | 10.99 | 8.85 | 5196 | 9.82370346 | CS |
52 | 0.1786 | 1.88 | 9.5 | 10.99 | 8.72 | 3973 | 9.6350936 | CS |
156 | -0.5714 | -5.57463414634 | 10.25 | 11.25 | 7.8 | 4591 | 9.14788356 | CS |
260 | 1.8386 | 23.4515306122 | 7.84 | 11.25 | 5.2 | 4944 | 8.56866792 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관